These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18456201)

  • 21. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous Implantable Cardioverter Defibrillator: Early Experience.
    Souza FSO; Matos VS; Almeida MCV; Weiss SC; Rodrigues LHB; Lima PAG; Mattos DB
    Braz J Cardiovasc Surg; 2017; 32(6):498-502. PubMed ID: 29267613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary prevention of sudden cardiac death: one step forwards and one step backwards.
    Cain ME
    Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):115. PubMed ID: 16505838
    [No Abstract]   [Full Text] [Related]  

  • 24. Evidence rather than costs must guide use of the implantable cardioverter defibrillator.
    Delacretaz E; Schlaepfer J; Metzger J; Fromer M; Kappenberger L
    Am J Cardiol; 2000 Nov; 86(9A):52K-57K. PubMed ID: 11084101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ventricular fibrillation triggered by a pacemaker-mediated tachycardia protection algorithm.
    Galand V; Behar N; Martins RP
    Europace; 2017 Aug; 19(8):1342. PubMed ID: 28444182
    [No Abstract]   [Full Text] [Related]  

  • 26. Implantable cardioverter defibrillator as therapeutic option for sudden cardiac death secondary to severe coronary vasospasm.
    Fuertes J; Gallego P; Peinado R; Merino JL
    Int J Cardiol; 1998 Jan; 63(2):181-3. PubMed ID: 9510493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review.
    Dhoble A; Khasnis A; Olomu A; Thakur R
    Clin Cardiol; 2009 Aug; 32(8):E63-5. PubMed ID: 19455567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical impact of defibrillation testing at the time of implantable cardioverter-defibrillator insertion.
    Hadid C; Atienza F; Strasberg B; Arenal Á; Codner P; González-Torrecilla E; Datino T; Percal T; Almendral J; Ortiz M; Martins R; Martinez-Alzamora N; Fernandez Aviles F
    Cardiol J; 2015; 22(3):253-9. PubMed ID: 25179316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implantable Cardioverter Defibrillator Implantation with or Without Defibrillation Testing.
    Duffett S; El Hajjaji I; Manlucu J; Yee R
    Card Electrophysiol Clin; 2018 Mar; 10(1):119-125. PubMed ID: 29428133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How implantable cardioverter-defibrillators work and simple programming.
    Bryant RM
    Cardiol Young; 2017 Jan; 27(S1):S121-S125. PubMed ID: 28084970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iatrogenic Palpitations during Exercise in a Patient with a Dual Chamber Implantable Cardioverter-Defibrillator and Lead Dysfunction.
    Hasegawa K; Miyazaki S; Kaseno K; Tada H
    Int Heart J; 2019 Mar; 60(2):462-465. PubMed ID: 30626767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implantable cardioverter defibrillators in athletes: rationale for use and issues surrounding return to play.
    Lawless CE
    Curr Sports Med Rep; 2008; 7(2):86-92. PubMed ID: 22908402
    [No Abstract]   [Full Text] [Related]  

  • 34. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death.
    Kutyifa V; Vermilye K; Daimee UA; McNitt S; Klein H; Moss AJ
    Europace; 2018 Sep; 20(FI2):f225-f232. PubMed ID: 29905788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inappropriate implantable cardioverter-defibrillator therapy: many causes and many possible solutions.
    Zareba W
    Cardiol J; 2009; 16(5):391-3. PubMed ID: 19753515
    [No Abstract]   [Full Text] [Related]  

  • 36. The implantable cardiac defibrillator.
    Kamalvand K; Gill JS
    Br J Hosp Med; 1996 Jan 17-Feb 6; 55(1-2):37-41. PubMed ID: 8646390
    [No Abstract]   [Full Text] [Related]  

  • 37. Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?
    Frommeyer G; Zumhagen S; Dechering DG; Larbig R; Bettin M; Löher A; Köbe J; Reinke F; Eckardt L
    J Am Heart Assoc; 2016 Mar; 5(3):e003181. PubMed ID: 27068637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indications for an implantable cardioverter defibrillator (ICD).
    Aizawa Y; Chinushi M; Washizuka T
    Intern Med; 2004 May; 43(5):360-7. PubMed ID: 15206546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy.
    Patel C; Yan GX; Kocovic D; Kowey PR
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):705-11; discussion 712. PubMed ID: 20009081
    [No Abstract]   [Full Text] [Related]  

  • 40. Prolonged sustained ventricular fibrillation in a patient with dextrocardia and a left ventricular assist device.
    Bolzan B; Morani G; Tomei R; Tomasi L; Borio G; Ribichini FL
    J Cardiovasc Med (Hagerstown); 2019 Oct; 20(10):721-724. PubMed ID: 31389822
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.